M. Michelle Berrey - Concepedia

Author

M. Michelle Berrey

Also Known As

M Michelle Berrey, M. Berrey, M. M. Berrey, M. Michelle Berrey, M.M. Berrey, M. Michelle Berrey, Michelle Berrey, Michelle M Berrey, Michelle M. Berrey, Paul Baum

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

University of Washington Seno Medical (United States)Fred Hutch Cancer Center Research Triangle Park Foundation Gilead Sciences (United States)

About

M. Michelle Berrey is an author at University of Washington specializing in medicine, virology, and hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	2K
2	Natural Sciences	1	1	36
3	Public Health	1	1	15
4	Emergency Medicine	1	1	14
5	Epidemiology	1	1	15

M. Michelle Berrey

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Early establishment of a pool of latently infected, resting CD4 <sup>+</sup> T cells during primary HIV-1 infection Tae‐Wook Chun, Delphine Engel, M. Michelle Berrey, Proceedings of the National Academy of Sciences	1998	830
Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C Edward Gane, Catherine Stedman, Robert H. Hyland, New England Journal of Medicine	2013	754
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy Tae‐Wook Chun, Delphine Engel, Stephanie B. Mizell, Nature Medicine Primary ImmunodeficiencyAutoimmune DiseaseActive Anti-retroviral TherapyHuman RetrovirusImmunology	1999	407
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Edward Gane, Stuart K. Roberts, Catherine AM Stedman, The Lancet HepatologyHepatitis CViral HepatitisAntiviral TherapyHepatitis	2010	335
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Eric Lawitz, Jay Lalezari, Tarek Hassanein, The Lancet Infectious Diseases HepatologyHepatitis CGenotypes 1Viral HepatitisAntiviral Drug Development	2013	328
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial Kris V. Kowdley, Eric Lawitz, Israel Crespo, The Lancet Hepatitis CMulticentre Phase 2Viral HepatitisAntiviral Drug DevelopmentAntiviral Therapy	2013	296
Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment Uma Malhotra, Sarah Holte, Sujay Dutta, Journal of Clinical Investigation	2001	121
Treatment of Primary Human Immunodeficiency Virus Type 1 Infection with Potent Antiretroviral Therapy Reduces Frequency of Rapid Progression to AIDS M. Michelle Berrey, Timothy W. Schacker, Ann C. Collier, The Journal of Infectious Diseases	2001	113
Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults Jacob Lalezari, Melanie Thompson, Priny Kumar, AIDS	2005	111
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial M. Rodríguez‐Torres, Eric Lawitz, Kris V. Kowdley, Journal of Hepatology Viral HepatitisTreatment-naïve PatientsHcv Genotype 1HepatitisVirology	2012	105

Page 1